An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.

MLA

Chouaid, Christos, et al. “An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.” Advances in Therapy, vol. 40, no. 3, Mar. 2023, pp. 1187–203. EBSCOhost, https://doi.org/10.1007/s12325-022-02408-7.

APA

Chouaid, C., Bosquet, L., Girard, N., Kron, A., Scheffler, M., Griesinger, F., Sebastian, M., Trigo, J., Viteri, S., Knott, C., Rodrigues, B., Rahhali, N., Cabrieto, J., Diels, J., Perualila, N. J., Schioppa, C. A., Sermon, J., Toueg, R., Erdmann, N., … Wolf, J. (2023). An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in Therapy, 40(3), 1187–1203. https://doi.org/10.1007/s12325-022-02408-7

Chicago

Chouaid, Christos, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, et al. 2023. “An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.” Advances in Therapy 40 (3): 1187–1203. doi:10.1007/s12325-022-02408-7.